Temperature-Controlled Laser Therapy
Maculaser ERG-based technology enables real-time and personalized control of temperature of the retina during non-damaging ophthalmic laser treatments.
Our industry-disruptive goal is disease prevention by providing effective and safe laser treatments for retinal disorders that impact the everyday life of millions of people worldwide.
Key benefits and GOALS
Consistent treatment outcome
Significant reduction of the current $400B direct healthcare system cost caused by the management of retinal diseases.
Heat the fundus to the therapeutic temperature to induce regenerative effects of temperature elevation without damaging retinal tissue.
Lack of patient-specific thermal dosimetry and safety controls currently limit the efficacy and utilization of the treatments.
Electroretinography (ERG)-based temperature-control enables personalized non-damaging laser treatments consistently landing to the therapeutic target temperature.
SCIENCE & RESEARCH
Maculaser is currently preparing for the clinical trials after successful preclinical tests, which demonstrated that the core dosimetry technology works, and also showed that the treatment successfully activates the cellular-level heat shock response as expected.
Maculaser is a clinical phase medical technology company developing novel laser therapy for retinal diseases. Company’s technology solution enables real-time and personalized control of therapeutic heat dose in the retina during non-damaging ophthalmic laser treatments.
Our history dates back to 2013 to a research focusing on controlled induction of therapeutic heat shock proteins in the retinal pigment epithelium layer in order battle degenerative changes in the eye. The invention to use electroretinography (ERG) signal to control laser–induced retinal heating initiated the ongoing research program in the team of Prof. Ari Koskelainen at the Department of Neuroscience and Biomedical Engineering, Aalto University, Finland, in collaboration with leading AMD and medical retina specialists from various university hospitals. The science behind Maculaser deep tech solution has already been tested in peer-reviewed scientific publications (see below).
Company’s industry-disruptive goal is to make early disease prevention a reality by providing effective and safe use of lasers for central macular disorders that impact the everyday life of millions of people worldwide.
Maculaser in scientific literature
Kaikkonen, O., Turunen, T., Amirkavei, M., Meller, A., Åhlgren, J., Temperature-controlled subthreshold laser therapy of pig retina, in preparation
Kaikkonen, O., Turunen, T., Amirkavei, M., Meller, A., Åhlgren, J., Retinal temperature determination based on photopic porcine electroretinogram, in review
Amirkavei, M., Pitkänen, M., Kaikkonen, O., Kaarniranta, K., André, H., & Koskelainen, A. (2020). Induction of Heat Shock Protein 70 in Mouse RPE as an In Vivo Model of Transpupillary Thermal Stimulation. International Journal of Molecular Sciences, 21(6). https://doi.org/10.3390/ijms21062063
Pitkänen, M., Kaikkonen, O., & Koskelainen, A. (2017). A Novel Method for Mouse Retinal Temperature Determination Based on ERG Photoresponses. Annals of Biomedical Engineering, 45(10), 2360–2372. https://doi.org/10.1007/s10439-017-1872-y
Pitkänen, M., Kaikkonen, O., & Koskelainen, A. (2019). In vivo monitoring of mouse retinal temperature by ERG photoresponses. Experimental Eye Research. https://doi.org/10.1016/j.exer.2019.05.015
Chief Scientific Officer, Co-Founder
Get in touch
c/o Terkko Health Hub, Building 14
00290 Helsinki, Finland
We are currently looking for co-operation with:
- medical retina specialists
- medtech investors
- industrial partnerhips in the field of ophthalmic lasers and optics